Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of ...

CRL has consistently achieved ROE values above 12% since 2018. In addition, in the same period, its liabilities-to-assets ratio has exhibited a downward trend. The company has seen a considerable ...

The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River ...

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Get the latest news on Charles River stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Charles River performance ...

Charles River Laboratories (CRL) reported $1.06 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 8.9%. EPS of $2.69 for the same period compares to $2.77 a ...

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.